Expansion of Cambrex’s Milan site makes room for APIs

By Maggie Lynch

- Last updated on GMT

(Image: Getty/LewisTsePuiLung)
(Image: Getty/LewisTsePuiLung)

Related tags API Cambrex italy R&D Manufacturing facility Laboratory

Cambrex completes expansion of its R&D laboratory at its Milan site and adds a 12,000-liter reactor to its manufacturing facility during a $3m investment.

The analytical services provider, Cambrex Corporation, completed the expansion of its site in Milan, Italy. The site now holds a new 150m2 ​R&D laboratory.

Cambrex’s expanded R&D laboratory has both chemistry and analytical development capabilities, after the installation of semi-automated glass-line reactors, multiple high and ultra-performance liquid chromatography, and gas chromatography systems.

A spokesperson for Cambrex told us the expansion enables the company to work on new projects at the site and expand its active pharmaceutical ingredients (APIs) portfolio.

“The patents of many important drugs are coming to an end; therefore, the site is working on new generic products. The investments that have been made in R&D at the site over the last two years have increased the capabilities in development, including the installation of containment facilities at a small scale to allow for the development of potent and highly potent APIs,” ​the Cambrex spokesperson said.

The new laboratory also holds a flow chemistry system for continuous manufacturing development, which the spokesperson said will enable researchers to “look at efficient synthetic routes for APIs and intermediates to generic APIs, where appropriate,” ​added the spokesperson.

Cambrex’s generic API portfolio covers drugs across therapeutic areas including analgesics, anesthesia, and central nervous system disorders.

Additionally, the company installed a 12,000-liter reactor to a current good manufacturing practice (cGMP) manufacturing facility at the Milan location.

The installation of the 12,000-liter reactor, among other updates, was part of a $3m (€2.65m) investment by the company to bolster the intermediates and generic APIs efficiency.

Related news

Show more

Related products

A Guide Through the API Drug Development Pipeline

A Guide Through the API Drug Development Pipeline

Content provided by Lonza Small Molecules | 11-Jul-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 09-Jun-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...

Related suppliers

Follow us


View more